Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis
- PMID: 31039160
- PMCID: PMC6490897
- DOI: 10.1371/journal.pone.0214131
Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis
Abstract
Background: Assessing Mycobacterium tuberculosis (TB) viability by fluorescein diacetate (FDA) microscopy can predict TB culture results, treatment response and infectiousness. However, diverse methods have been published. We aimed to optimise FDA microscopy, minimising sputum processing, biohazard and complexity for use in resource-constrained settings.
Methods and results: Optimization: Patients with smear-positive pulmonary TB before treatment and healthy control participants provided sputa. These were divided into equal aliquots that were tested directly or after NaOH centrifuge-decontamination. Each aliquot was cultured and used to prepare slides (n = 80). FDA microscopy used: 1 or 3 drops of sputum; with/out acid-alcohol wash; with/out phenol sterilization; with 0/30/60 seconds KMnO4 quenching. Control samples all had negative culture and microscopy results. FDA microscopy had higher sensitivity when performed directly (without centrifuge-decontamination) on 1 drop of sputum (P<0.001), because 3 drops obscured microscopy. Acid-alcohol wash and KMnO4 quenching made bacilli easier to identity (P = 0.005). Phenol sterilization did not impair microscopy (P>0.1). Validation: The 2 protocols that performed best in the optimization experiments were reassessed operationally by comparing duplicate slides (n = 412) stained with KMnO4 quenching for 30 versus 60 seconds. FDA microscopy results were similar (P = 0.4) and highly reproducible, with 97% of counts agreeing within +/-1 logarithm. Storage: Smear microscopy slides and aliquots of the sputum from which they were made were stored for 4 weeks. Twice-weekly, paired slides (n = 80) were stained with freshly prepared versus stored FDA and read quantitatively. Storing sputum, microscopy slides or FDA solution at 4°C or room temperature had no effect on FDA microscopy results (all P>0.2). Cost: Material costs for each slide tested by FDA microscopy using reagents purchased locally were USD $0.05 and required the same equipment, time and skills as auramine acid-fast microscopy.
Conclusions: We recommend a simple, bio-secure protocol for FDA microscopy that provides sensitive and repeatable results without requiring centrifugation.
Conflict of interest statement
All the authors declare that they have no competing interests exist in relation to this publication. The corresponding author had full access to all study data and was responsible for the decision to publish.
Figures
References
-
- World Health Organisation. Global tuberculosis report 2017 [Internet]. 2017. Available from: http://www.who.int/tb/publications/global_report/en/
-
- MacPherson P, Houben RMGJ, Glynn JR, Corbett EL, Kranzer K. Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. Bull World Health Organ [Internet]. 2014;92(2):126–38. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3949536&tool=p... 10.2471/BLT.13.124800 - DOI - PMC - PubMed
-
- Datta S, Shah L, Gilman RH, Evans CA. Comparison of sputum collection methods for tuberculosis diagnosis: a systematic review and pairwise and network meta-analysis. Lancet Glob Heal [Internet]. 2017. August [cited 2017 Dec 8];5(8):e760–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28625793 - PMC - PubMed
-
- Kvach J, Veras J. A fluorescent staining procedure for determining the viability of Mycobacterial cells. Int J Lepr. 1982;50(2):183. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
